Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis.

  1. Inicio
  2. »
  3. Sin categoría
  4. »
  5. Denosumab or romosozumab therapy and risk of cardiovascular events in...
Patrocinadores de la web
Lilly
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen
Gebro
Faes Farma
Meiji Pharma